Jubilant Life increases Vitamin B3 price by nearly 15%
Jubilant Life Sciences on Thursday announced an increase of up to 15 per cent in the price of its Vitamin B3 (Niacin and Niacinamide) with immediate effect. The price increase is for non-contract... Updates
Jubilant announces price increase of up to 15% for Vitamin B3 (Niacin & Niacinamide) Jubilant Life shares jump 7 pc on stellar Q4 show
Shares of Jubilant Life Sciences today soared 7 per cent after the company's consolidated net profit zoomed nearly 14fold for the March quarter. The stock jumped 6.60 per cent to settle at Rs 723... Appointment of Director
Jubilant Life Sciences Ltd has informed BSE that the Board has, at its meeting held on May 23, 2017, appointed the following Additional Directors effective from May 23, 2017:1. Mr. Vivek Mehra and Mr. Sushil Kumar Roongta as Independent Directors.2. Mr. Priyavrat Bhartia and Mr. Arjun Shanker Bhartia as Non-Executive Non-Independent Directors.... Updates
Compliance with Regulation 52(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Board recommends Dividend
Jubilant Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 23, 2017, inter alia, has recommended a dividend of Rs. 3 (Rupees Three only) per equity share of Re.1 each for the year ended March 31, 2017. The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the Company, will be paid / dispatched on or before September 27, 2017. Audited Financial Results For The Quarter And Year Ended March 31, 2017
1.The Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2017; 2.Audit Reports for Standalone and Consolidated Financial Results; 3.Copies of the Press Release and Presentation. We declare that the Reports of Auditors are with unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2017. Outcome of Board Meeting
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on May 23, 2017, recommended a dividend of Rs. 3 (Rupees Three only) per equity share of Re.1 each for the year ended March 31, 2017. The dividend, if approved by the shareholders at the ensuing... Jubilant gets USFDA nod for generic hypertension drug
Jubilant Life Sciences has received approval from the US health regulator to market amlodipine and olmesartan medoxomil tablets, used to treat hypertension, in the American market. Jubilant...